Molecular imaging plays a vital role in the management of neuroendocrine neoplasms
(NENs). Somatostatin receptor (SSTR) PET is critical for evaluating NENs, ascertaining …

Background: this study aims to explore the prognostic and predictive role of volumetric
parameters on [68Ga] Ga-DOTATOC PET/CT in neuroendocrine tumors (NET) patients …

There is great demand to enhance the efficacy of PRRT through combination with other
anticancer treatments. While research in this area is currently limited, the field is rapidly …

Peptide receptor radionuclide therapy (PRRT) today is a well-established treatment strategy
for patients with neuroendocrine tumors (NET). First performed already more than 30 years …

The carcinoid syndrome (CS) and hyperinsulinemic hypoglycemia (HH) represent two of the
most common clinical syndromes associated with neuroendocrine neoplasms (NENs). The …

Gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) are one of the most common
types of NETs, accounting for 65‑75% of all NETs. However, epidemiological characteristics …

The third edition of the EANM Focus Meeting series was held in Athens, Greece, at the end
of January 2020. There we had the pleasure and honour of conducting the consensus …

Neuroendocrine neoplasms (NENs) are a diverse group of tumors originating from
neuroendocrine cells present throughout the body. 1 These tumors share common …

Neuroendocrine neoplasms (NENs) are a diverse group of tumors with varying clinical
behaviors. Their incidence has risen due to increased awareness, improved diagnostics …

The overexpression of one or more somatostatin receptors (SST1–5R) in human tumors has
provided an opportunity for diagnosis and therapy with somatostatin-like radionuclide …